briefing documents for moderna and pfizer, with one dose they reached about 35 to 45%. it was the second dose that got them to 94 or 95%. so it s the same two-dose regiment as moderna and pfizer. even though one dose is appealing to a lot of people, even though the efficacy rate is a little low, it does inspire more people who actually get vaccinated? no, absolutely. we certainly have groups that absolutely benefit from this johnson & johnson vaccine. and we want to have always remember that. and also, we want to know that it was 100% protected against death and hospitalization. those were the main end points. although there s slightly less efficacy, with regard to symptomatic infections, the main end points of complications and death are very real.
problem with the fact that it was sold as a one shot wonder with a lower efficacy. you think it was still important to have that out there and you like the idea even more now that the efficacy rate is much higher with johnson & johnson with a booster shot? absolutely. and i don t think that the american people should be upset or confused by this at all. the nature of science is that it evolves as we get more information. data changes and thus our recommendations change. okay. all right. so for now, let s also talk about what else is potentially available. the fda is officially side stepping for now, the question of whether people can mix and match vaccine shots and boosters. while it looks at the data, there is one study in the u.k. that suggests it is effective. what are you telling patients who ask? so i m going to sidestep this a little bit as well and preface my answer by saying this is not medical advice and you should still talk to your physician
themselves, from a scientific standpoint and their efficacy rate has been really good. now it s true, the efficacy of some of the vaccines in terms, preventing infection, have taken a bit of a hit with the delta variant. but, they have held up incredibly well in protecting against serious illness and death. places that are highly vaccinated like, vermont which have been a model for battling covid with the republican governor in charge, i will add, vermont is already seen that protection inaction. more than 87% of the eligible population in vermont has received at least one dose, and as a result they did not see a huge new wave of cases hospitalization, and that from delta. so far they have been spared the misery of waves of deaths that we ve seen in states like florida and mississippi. mississippi in fact, now has the highest rate of covid deaths per capita in the country. surpassing the states hardest hit at the very beginning of the pandemic, states like new jersey and new york. and
the coronavirus pandemic. there are over 42 million cases in the u.s., and 676,000 deaths, and that means roughly 1 in 500 americans have died from the virus. meanwhile, an fda advisory panel voted against recommending a third shot of the pfizer vaccine to eligible americans at large, but they are recommending it for adults 65 and older and those considered high risk. this comes amid concerns by the cdc that the protection provided by the vaccines may be waning. in a new report, it shows it drops in efficacy after four months, and moderna has relatively the same efficacy rate, 92% to 93% after 120 days. there is a surge in new covid cases across the country and those are straining health care workers and limiting hospital resources in states like
about hesitancy and the fact that the vaccine is not working. it s a strategic error to not level with the american people and say this is a vaccine. like any of her drug, it has a efficacy rate. johnson & johnson is about 70% effective. 30% of cases folks are vulnerable. it stands to reason to open the door for americans to determine the status of their immunity. it s the single most critical parameter in terms of your personal susceptibility to covid-19 infection. by the fda blocking that information, it s personal health information the fda s introducing hesitancy to comets or dramatic mistake. it s antiscience coming out of the u.s. fda. shannon: will see if the president touches on these things. immunity versus vaccination and the fact that everybody across the country should have a look at antibodies so they can make good decisions. doctor, we appreciate your expertise. thanks for weighing in. first up into nights real news roundup. the national archives website which keeps dig